Veterinary Medicine Information website

Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle

Authorised
  • Penethamate hydriodide
  • Benethamine penicillin
  • Framycetin sulfate
Download as PDF

Product identification

Medicine name:
Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle
Active substance:
  • Penethamate hydriodide
  • Benethamine penicillin
  • Framycetin sulfate
Target species:
  • Cattle
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Penethamate hydriodide
    100.00
    milligram(s)
    /
    1.00
    Syringe
  • Benethamine penicillin
    280.00
    milligram(s)
    /
    1.00
    Syringe
  • Framycetin sulfate
    100.00
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary suspension
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle
      • Meat and offal
        10
        day
      • Milk
        37
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51RC25
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • Cardboard box or plastic container containing 120 single useintramammary syringes and 120 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.
  • Cardboard box or plastic container containing 60 single useintramammary syringes and 60 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.
  • Cardboard box or plastic container containing 20 single useintramammary syringes and 20 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Haupt Pharma Latina S.r.l.
  • Lohmann Pharma Herstellung GmbH
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V408003
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0271/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Czechia
  • France
  • Hungary
  • Netherlands
  • Poland
  • Romania
  • Slovakia
  • Slovenia
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 23/08/2024
Download
Dutch (PDF)
Published on: 18/08/2025
Download
French (PDF)
Published on: 18/08/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 18/08/2025
Download
German (PDF)
Published on: 18/08/2025
Download
Dutch (PDF)
Published on: 18/08/2025
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 18/08/2025
Download
German (PDF)
Published on: 18/08/2025
Download
Dutch (PDF)
Published on: 18/08/2025
Download